Diabeloop
- Industry
- Medical Devices & Instruments
- Founded Year
- 2015
- Headquarters
- Grenoble, France
- Employee Count
- 117
Key People
- Erik Huneker - Founder & CEO
- Catherine Dunand - Chairman of the Board
-
Stphanie Jgu - Press Contact
Email: stephanie.jegu@diabeloop.com
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with a strong background in medical technology and entrepreneurship.
Diabeloop's leadership includes individuals with proven track records in MedTech, enhancing the company's credibility and operational effectiveness.
- Clinical Need
-
Aspect: Very Strong
Summary: Diabeloop addresses a critical need in diabetes management by automating insulin delivery, significantly improving patient outcomes and quality of life.
By reducing the mental burden of diabetes management and enhancing glycemic control, Diabeloop's technology fulfills a significant unmet need in the healthcare market.
- Competition
-
Aspect: Very crowded + Strategics
Summary: The market for automated insulin delivery systems is highly competitive, with several established players and strategic partnerships.
Diabeloop faces competition from companies like Unigluko, Insulclock, Reapplix, and GlySens, all offering innovative diabetes management solutions.
- Technical Challenge
-
Aspect: Predictable
Summary: The development of AI-driven insulin delivery systems involves complex but manageable technical challenges.
Diabeloop's expertise in AI and medical device development enables it to effectively address the technical complexities inherent in its product offerings.
- Patent
-
Aspect: Strong
Summary: Diabeloop holds a robust patent portfolio, providing a competitive edge in the market.
A solid patent portfolio safeguards Diabeloop's proprietary technologies, deterring competitors and supporting long-term success.
- Financing
-
Aspect: Well-funded
Summary: Diabeloop has secured substantial funding, including a 70 million Series C round, supporting its growth and expansion plans.
Significant investment from reputable investors enables Diabeloop to accelerate product development, expand internationally, and enhance its market presence.
- Regulatory
-
Aspect: 510k/PMA
Summary: Diabeloop has obtained CE marking for its products and is pursuing FDA approval for entry into the U.S. market.
Achieving CE marking and advancing towards FDA approval demonstrate Diabeloop's commitment to meeting stringent regulatory standards, essential for market acceptance and growth.
Opportunity Rollup
- Odds of Success
- 3.7
- Peak Market Share
- 4.9
- Segment CAGR
- 9.5%
- Market Segment
- Medical Devices & Instruments
- Market Sub Segment
- Automated Insulin Delivery Systems
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.24 |
| 2 | 0.73 |
| 3 | 1.71 |
| 4 | 3.43 |
| 5 | 4.90 |
Key Takeaway
Diabeloop's innovative AI-driven insulin delivery solutions address a critical need in diabetes management, supported by strong leadership and substantial funding, positioning the company for significant growth despite a competitive market landscape.